MedTrace Logo

Efficacy of L-methylfolate and Methylcobalamine in Treating Resistant Hypertension Associated with Elevated Serum Homocysteine in Hemodialysis Patients.

NCT05807711 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-01-13

No results posted yet for this study

Summary

The aim of the study is to evaluate the efficacy of L-methylfolate in combination with methylcobalamine in reducing homocysteine blood levels in hypertensive end-stage renal disease patients on regular hemodialysis and its association with blood pressure control in treatment of resistant hypertension

Conditions

Interventions

DRUG

L-Methyl Folate and methylcobalamine

Dietary supplement labeled to contain methylfolate 800 micrograms and methylcobalamine 1000 micrograms

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Hanan M El-gowelli, PhD · Professor of Pharmacology & Toxicology, Alexandria University

  • Hesham A Elghoneimy, PhD · Associate Professor of Internal Medicine, Alexandria University

  • Noha A Hamdy, PhD · Associate Professor of Clinical Pharmacy, Alexandria University

  • Mohamed S Salem, PharmD · Master's student in Clinical Pharmacy and Pharmacy Practice, Alexandria University.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05807711 on ClinicalTrials.gov